QuantHealth — AI-Driven Clinical Trial Simulations
ENTITYQuantHealth has raised $45 million in Series B funding to expand its AI platform that simulates clinical trials before they run and predicts patient outcomes for pharmaceutical companies. The platform aims to address the pharmaceutical industry's persistent 90% clinical trial failure rate by enabling sponsors to identify optimal trial designs, patient populations, and endpoint selections before committing to expensive human trials. QuantHealth's approach uses AI to model trial outcomes based on real-world patient data, prior clinical trial results, and biological pathway knowledge. By simulating trial performance computationally, the platform can identify design flaws, predict enrollment challenges, and estimate efficacy signals — potentially saving years of development time and billions in failed trial costs. The $45M Series B reflects continued investor confidence in AI-driven clinical trial optimization as a high-value pharmaceutical application. QuantHealth competes in an emerging category alongside companies like Unlearn.ai (digital twins for clinical trials) and Insilico Medicine (AI-driven trial design), with the shared thesis that computational simulation can fundamentally improve the economics of drug development. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.